- Home
- KE vs SAGE Comparison
KE vs SAGE Comparison
Compare KE & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KE
- SAGE
- Stock Information
- Founded
- KE 1961
- SAGE 2010
- Country
- KE United States
- SAGE United States
- Employees
- KE N/A
- SAGE N/A
- Industry
- KE Electrical Products
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- KE Technology
- SAGE Health Care
- Exchange
- KE Nasdaq
- SAGE Nasdaq
- Market Cap
- KE 442.5M
- SAGE 415.0M
- IPO Year
- KE N/A
- SAGE 2014
- Fundamental
- Price
- KE $14.57
- SAGE $7.79
- Analyst Decision
- KE Buy
- SAGE Hold
- Analyst Count
- KE 5
- SAGE 19
- Target Price
- KE $22.20
- SAGE $9.88
- AVG Volume (30 Days)
- KE 148.5K
- SAGE 1.2M
- Earning Date
- KE 05-06-2025
- SAGE 04-29-2025
- Dividend Yield
- KE N/A
- SAGE N/A
- EPS Growth
- KE N/A
- SAGE N/A
- EPS
- KE 0.32
- SAGE N/A
- Revenue
- KE $1,586,842,000.00
- SAGE $41,243,000.00
- Revenue This Year
- KE N/A
- SAGE $100.64
- Revenue Next Year
- KE N/A
- SAGE $70.19
- P/E Ratio
- KE $45.26
- SAGE N/A
- Revenue Growth
- KE N/A
- SAGE N/A
- 52 Week Low
- KE $12.41
- SAGE $4.62
- 52 Week High
- KE $24.45
- SAGE $14.97
- Technical
- Relative Strength Index (RSI)
- KE 49.06
- SAGE 56.30
- Support Level
- KE $13.73
- SAGE $7.56
- Resistance Level
- KE $14.19
- SAGE $7.89
- Average True Range (ATR)
- KE 0.79
- SAGE 0.36
- MACD
- KE 0.19
- SAGE 0.06
- Stochastic Oscillator
- KE 95.15
- SAGE 88.03
About KE Kimball Electronics Inc.
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.